Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
virus-specific cytotoxic T-lymphocytes (Western Sydney Local Health District)
- Development stage
- Unknown
- Lead developer
- Atara Biotherapeutics
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
Virus-specific cytotoxic T-lymphocytes (VSTs) are an investigational cell-based biologic therapy being studied for the treatment of viral infections in immunocompromised patients. This specific program, developed by the Western Sydney Local Health District, utilizes third-party donor-derived T-cells that are expanded ex vivo and selected based on HLA matching. The therapy is designed to reconstitute antiviral immunity against cytomegalovirus (CMV), adenovirus, and Epstein-Barr virus (EBV) in patients who have undergone allogeneic hematopoietic stem cell transplantation (HSCT) and whose infections are persistent or refractory to standard antiviral medications. By adoptively transferring these specialized T-cells, the treatment aims to provide a targeted immune response to clear or control viral reactivation.
- Other names
- virus-specific T-cellsVSTsmultivirus-specific T-cellsthird-party donor-derived virus-specific cytotoxic T-lymphocytes
02
Targets
Cytomegalovirus phosphoprotein 65 and immediate-early protein 1 peptides presented by human leukocyte antigen class I and class IIpMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on virus-specific cytotoxic T-lymphocytes (Western Sydney Local Health District).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on virus-specific cytotoxic T-lymphocytes (Western Sydney Local Health District).